*By Christian Smith*
After an overdose earlier this week, Demi Lovato's life was reportedly saved by Narcan, a nasal administrator of naloxone that counteracts the effects of opioids. When administered quicklyーthrough either nasal mist or injectionーnaloxone can temporarily halt an overdose, allowing EMTs enough time to respond. The medication is available without a prescription in 49 states, and the generic version costs about $20 per dose.
But all merits aside, is the drug's accessibility enabling addicts to push their limits?
Dr. Roger Crystal, the lead inventor of Narcan and CEO of Opiant Pharmaceuticals, says there's little evidence to support that concern.
"Addiction like any kind of chronic disease is something you can control using better medication, but ultimately you can't cure," Crystal told Cheddar. "To think about an opioid addict behaving rationally and saying, 'well because I have access to Narcan I'll shoot more heroin, inject more heroin' there's no proof for that whatsoever."
Naloxone is considered some of the best ammunition on the front lines of America's growing opioid epidemic. A reported 2 million Americans have an addition to opioidsーand the number isn't going down. U.S. Surgeon General Jerome Adams [issued an advisory](https://www.surgeongeneral.gov/priorities/opioid-overdose-prevention/naloxone-advisory.html) in April urging anyoneーand their close family and friendsーwho uses painkillers, heroin, fentanyl, or other opioids to carry naloxone in case of an emergency.
Crystal isn't stopping at Narcan: he told Cheddar he's also developing a heroin vaccine, suggesting the inventor has lofty ambitions for the future of overdose prevention.
Although Crystal may be aware of lingering ethical concerns, he doesn't think they dwarf his mission. After all, Lovato has him to thank.
"Putting it in the hands of everyone and anyone is critical," Crystal said.
For more on this story, [click here](https://cheddar.com/videos/how-one-pharmaceutical-company-is-fighting-the-opioid-epidemic).
Carlo and Baker cover the latest data showing the Omicron wave has likely started, Pfizer's Covid pill, Jan. 6 and a box office rescue attempt courtesy of Spider-Man.
Upward Farms is an indoor vertical farming company on a mission to heal our broken food system and reconnect consumers with organic locally-grown food. The Brooklyn-based company uses its controlled environment farms to grow organic leafy greens, which are sold at whole foods markets in New York City. Upward Farms co-founder and CEO Jason Green joined Cheddar Climate to discuss.
One of the biggest hurdles when it comes to widespread electric vehicle adoption is consumer hesitation about their ability to keep their EV charged if they take a longer trip outside of their locality. Now, electric companies nationwide are teaming up as part of a coalition to build out a network of EV charging stations spanning major U.S. travel corridors. Kellen Schefter, director of electric transportation at the Edison Electric Institute, joins Cheddar Climate to discuss the coalition's plans, how drivers can compare fueling up with gas to recharging an EV on a long trip, how the charging network will be funded, and more.
As more states begin to legalize recreational marijuana, there's a growing interest in legalizing cannabis cultivation. As the rise in cannabis farms expands across the U.S., more research is being done to examine its impact on the planet. Michael Katz, executive director at Mendocino Cannabis Alliance, joins Cheddar News to talk about the carbon footprint of cannabis farms.
Blue Origin launched its third manned mission over the weekend with 'Good Morning America' host Michael Strahan and Laura Shepard Churchley, daughter of astronaut Alan Shepard on board, alongside several Blue Origin investors.
This comes after the spaceflight firm launched two successful missions to the edge of space earlier this year. How will these missions set up Blue Origin for success as it competes with SpaceX and other companies for space tourism domination and more? Joey Roulette, space reporter at The New York Times, joins Cheddar News' Closing Bell to discuss.
Mina Makar, senior vice president of respiratory and immunology, Astrazeneca, joined Cheddar to discuss the FDA's decision to give emergency use authorization to the pharma giant's COVID-19 antibody treatment called Evusheld for immunocompromised patients For about 2 percent of the U.S. Makar noted that the injection is supposed to provide antibody protection for those who can't generate their own adequate immune response via the vaccines for a minimum of six months, though long-term trials are underway.
The pandemic has forced corporate America to reshape itself to adapt, including onboarding doctors as chief medical officers to help maintain the health and safety of staff. Dr. Geeta Nayyar, chief medical officer at Salesforce, joined Cheddar to break down her role and how it has become relevant and necessary in the evolving workplace. "Every business today is now in the business of healthcare," she said. "It is a priority to empower employees to then serve your customers."
Jonathan Adler, Law Professor at Case Western Reserve University, joined Wake Up With Cheddar to discuss Tuesday's ruling and provide legal context to recent battles over vaccine mandates.
Carlo and Baker wrap up the week talking about the Biden economic boom that no one seems to notice, a verdict in the Jussie Smollett case, the first Starbucks union in America and the pleasures of the "dude nod."
